

40% Glucose gel

Newborn use only

2018

Alert	Glucose gel is to be massaged into the buccal mucosa. It is not be administered/squirted straight into the mouth to avoid the risk of aspiration from gel. Oral glucose gel, on average, raises blood glucose by 0.4 mmol/L (95% CI -0.14–0.14) ² and is not the option for moderate to severe hypoglycaemia.
Indication	Prevention and treatment of mild hypoglycaemia in neonates ≥35 weeks' gestation and <48 hours of life ^{1,2}
Action	Glucose gel contains glucose, a simple carbohydrate, in concentrated aqueous solution, which can be administered by direct application to mucosal surfaces of the mouth, including buccal and lingual surfaces. Absorption from these sites may allow rapid access to the circulation. Some proportion of the dose may be swallowed and absorbed from the gastrointestinal tract. ²
Drug Type	40% Glucose (Dextrose) Gel
Trade Name	SugarUp 40% glucose gel (15 mL cup).
Presentation	SugarUp 40% glucose gel (15 mL cup). Contains 40% dextrose (D-glucose), glycerine, USP purified water, maltodextrin, carboxymethyl cellulose, and citric acid (buffer).
Dosage/Interval	0.5 mL/kg/dose (200 mg/kg/dose). ³ Doses can be repeated as per the local hospital guidelines. 1 mL/kg/dose (400 mg/kg/dose) as a single dose has also been used. ⁵
Route	ORAL – Massaged onto buccal mucosa. DO NOT squirt gel directly into baby's mouth.
Maximum Daily Dose	1.5 mL/kg
Preparation/Dilution	
Administration	<ol style="list-style-type: none"> 1. Open container. 2. Draw up required dose of gel very slowly in an oral-only 5 mL syringe. 3. Tap out any air bubbles. 4. Dry baby's mouth with gauze. DO NOT Squirt gel directly into the baby's mouth. 5. Dispense one-half of the dose from oral syringe onto gloved finger, in a stream – not a glob. 6. Massage into the buccal mucosa of one cheek. 7. Repeat with remaining half-dose inside the other cheek. 8. Large doses may be divided into 4 equal amounts and given alternating between cheeks. 9. Discard unused gel in container. 10. Commence breastfeeding or administer expressed breast milk or formula. 11. Monitor infant according to hospital guideline.
Monitoring	Measure blood glucose 30 minutes after administration and subsequent management is as per the hospital guideline.
Contraindications	No information.
Precautions	<35 weeks gestation; infants at risk of aspiration or in whom feeds are contraindicated.
Drug Interactions	No information.
Adverse Reactions	Risk of aspiration if the gel is squirted directly into mouth.
Compatibility	No information.
Incompatibility	No information.
Stability	12-month shelf life. Check the expiry date prior to administration.
Storage	Keep at room temperature. Single patient use only. Discard after opening.
Special Comments	Oral glucose gel, on average raises blood glucose level by 0.4 mmol/L (95% CI -0.14–0.14). ²
Evidence summary	Prevention of neonatal hypoglycaemia Hegarty et al, in a systematic review, assessed the effectiveness and safety of oral dextrose gel in preventing hypoglycaemia among newborn infants at risk of hypoglycaemia and in reducing long-term neurodevelopmental impairment. They included one trial comparing oral dextrose gel versus placebo in 416 infants at risk of hypoglycaemia, most of whom were infants of diabetic mothers and were treated on the postnatal ward. Oral dextrose gel prophylaxis (any dose) was associated with reduced risk of hypoglycaemia compared with placebo (risk ratio (RR) 0.76, 95% confidence interval (CI) 0.62 to 0.94). There were no statistically significant differences in the number of adverse events, separation from mother for treatment of hypoglycaemia, exclusive breastfeeding at discharge or breastfeeding at six weeks postpartum. They concluded that oral dextrose gel reduced the risk of neonatal hypoglycaemia in at-risk infants with no statistically significant differences in the number of adverse events or in risk of separation of infant from

	<p>mother for treatment of hypoglycaemia [LOE 1, GOR A]</p> <p><u>Treatment of neonatal hypoglycaemia</u></p> <p>Weston et al, in a systematic review, assessed the effectiveness of dextrose gel in correcting hypoglycaemia and in reducing long-term neurodevelopmental impairment in neonates at risk of hypoglycaemia.² They included two trials involving 312 infants. They found no significant difference between dextrose gel and placebo gel for major neurosensory disability at two-year follow-up (risk ratio (RR) 6.27, 95% confidence interval (CI) 0.77 to 51.03; one trial, n = 184; quality of evidence very low). Dextrose gel compared with placebo gel or no gel did not alter the need for intravenous treatment for hypoglycaemia (typical RR 0.78, 95% CI 0.46 to 1.32; two trials, 312 infants; quality of evidence very low). Infants treated with dextrose gel were less likely to be separated from their mothers for treatment of hypoglycaemia (RR 0.54, 95% CI 0.31 to 0.93; one trial, 237 infants; quality of evidence moderate) and were more likely to be exclusively breastfed after discharge (RR 1.10, 95% CI 1.01 to 1.18; one trial, 237 infants; quality of evidence moderate). Treatment of infants with neonatal hypoglycaemia with 40%dextrose gel reduces the incidence of mother-infant separation for treatment and increases the likelihood of full breast feeding after discharge compared with placebo gel. No excess of adverse effects have been reported during the neonatal period or at two years' corrected age. Oral dextrose gel has not been compared to supplementary feeding with human milk or formula. Oral dextrose gel may be considered as first-line treatment for infants with neonatal hypoglycaemia. [LOE 1, GOR A]</p>
<p>References</p>	<ol style="list-style-type: none"> Hegarty JE, Harding JE, Crowther CA, Brown J, Alsweiler J. Oral dextrose gel to prevent hypoglycaemia in at-risk neonates. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012152. DOI: 10.1002/14651858.CD012152.pub2. Weston PJ, Harris DL, Battin M, Brown J, Hegarty JE, Harding JE. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD011027. DOI: 10.1002/14651858.CD011027.pub2. Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. Lancet 2013;382(9910):2077–83. Harris D, Alsweiler J, Ansell J, Gamble G, Thompson B, Woulides T, et al. Outcome at 2 years after dextrose gel treatment for neonatal hypoglycaemia: follow-up of a randomized trial. Journal of Pediatrics 2016;170:54–9. Troughton KEV, Corrigan NP, Tait RME. Hypostop gel in the treatment of neonatal hypoglycaemia: a randomised controlled trial. Archives of Disease in Childhood 2000;82 (Suppl 1):A30.

Original version Date: 20/07/2018	Author: Neonatal Medicines Formulary Group
Current Version number: 1.0	Version Date: 20/07/2018
Risk Rating: Low	Due for Review: 20/07/2023

Authors Contribution

Original author/s	Srinivas Bolisetty
Evidence Review	David Osborn
Nursing Review	Eszter Jozsa
Pharmacy Review	Jing Xiao, Cindy Chen, Carmen Burman
NMF Group contributors	Nilkant Phad, Himanshu Popat
Final content and editing review of the original	Ian Whyte
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty